Latest news
Pancreatic Cancer’s ADC Moment Will Live or Die by the Biomarker
Early ESMO GI data suggest that a CEACAM5-targeted antibody–drug conjugate may have activity in selected patients with refractory pancreatic cancer. The opportunity is real. So is the danger of treating biomarker selection as a box-ticking exercise.
AI Eye Screening Has an Image Quality Problem
AI Retinal Screening Moves Into the Diabetes Clinic
India Turns AI Eye Screening Into Public-Health Infrastructure
Geographic Atrophy Forces Europe to Define Meaningful Vision Benefit
Eye Health Moves From Charity Case to Investment Case
Africa’s Cardiovascular Decade Is a System-Design Problem
Inherited Lipid Screening Becomes Europe’s Prevention Test
ATTR Gene Editing Restarts, But Safety Becomes the Access Question
Routine CT Scans Could Become a Heart Failure Early-Warning System
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.